{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,21]],"date-time":"2026-02-21T01:28:23Z","timestamp":1771637303894,"version":"3.50.1"},"reference-count":40,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2007,4,30]],"date-time":"2007-04-30T00:00:00Z","timestamp":1177891200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Viral Hepatitis"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:p><jats:bold>Summary.\u2002<\/jats:bold> We sought to corroborate geographical differences in hepatitis C virus (HCV) prevalence and assess whether these can be explained by differences in injecting risk behaviour. A community recruited interview survey of 1058 injecting drug users (IDU) \u2013 including a blood spot specimen for antibody testing \u2013 was undertaken in seven cities in England. HCV prevalence varied from 27% to 74% across sites (<jats:italic>\u03c7<\/jats:italic><jats:sup>2<\/jats:sup>(6)\u2003=\u2003115.3, <jats:italic>P<\/jats:italic>\u2003&lt;\u20030.001). There was a significant variation in crack\u2010injection, prison history, injecting frequency, homelessness, groin injecting, syringe reuse and sharing between the sites. Adjustment for clustering by site and other covariates attenuated the odds ratios (OR) for most variables: e.g. crack injection changed from an unadjusted OR of &gt;2 to an adjusted OR of 1.4 (95% CI 0.9\u20132.0). Remaining significant covariates included: homelessness (OR 2.2; 1.4\u20133.6); ever imprisonment (OR 1.7; 1.2\u20132.5); syringe sharing &gt;18\u2003months ago (OR 2.0; 1.3\u20133.0); injecting duration and age. Introducing site as a second level variable did not reach significance (<jats:italic>P<\/jats:italic>\u2003=\u20030.10). HCV prevalence among IDU reporting \u2018never sharing\u2019 was 48%. Geographical variation in HCV prevalence remains poorly explained, but should be the key focus of our surveillance effort. Measures of sharing and their interpretation require greater scrutiny.<\/jats:p>","DOI":"10.1111\/j.1365-2893.2007.00855.x","type":"journal-article","created":{"date-parts":[[2007,5,7]],"date-time":"2007-05-07T12:41:31Z","timestamp":1178541691000},"page":"645-652","source":"Crossref","is-referenced-by-count":83,"title":["Hepatitis C virus (HCV) prevalence, and injecting risk behaviour in multiple sites in England in 2004"],"prefix":"10.1111","volume":"14","author":[{"given":"M.","family":"Hickman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Hope","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Brady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Madden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Honor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Ncube","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Parry","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,4,30]]},"reference":[{"key":"e_1_2_6_2_2","volume-title":"Shooting Up: Infections among Injecting Drug Users in the United Kingdom 2004","author":"Health Protection Agency, Health Protection Scotland, National Public Health Service for Wales, CDSC Northern Ireland, CRDHB, and the UASSG","year":"2005"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1016\/0277-9536(94)00435-V"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.91.1.38"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38286.841227.7C"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-93"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.aids.0000176222.71355.a1"},{"key":"e_1_2_6_8_2","volume-title":"Initiating Second Generation HIV Surveillance Systems: Practical Guidelines","author":"UNAIDS\/WHO","year":"2002"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-199311000-00015"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1542\/peds.32.3.338"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1002\/jmv.10463"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-0038-1634008"},{"key":"e_1_2_6_13_2","volume-title":"A User's Guide to MLwiN","author":"Rasbash J","year":"2005"},{"key":"e_1_2_6_14_2","first-page":"216","article-title":"Hepatitis B and hepatitis C seroprevalence and risk behaviour among community\u2010recruited drug injectors in North West Wales","volume":"7","author":"Craine N","year":"2004","journal-title":"Commun Dis Public Health"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1017\/S0950268802007902"},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1136\/jech.51.6.692"},{"issue":"5","key":"e_1_2_6_17_2","first-page":"423","article-title":"HIV and HCV infection among injecting drug users","volume":"67","author":"Hagan H","year":"2000","journal-title":"Mt Sinai J Med"},{"key":"e_1_2_6_18_2","unstructured":"European Monitoring Centre on Drugs and Drug Addiction (EMCDDA)Available at:http:\/\/stats06.emcdda.europa.eu\/en\/elements\/inftab03\u2010en.html(accessed March 2007)."},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.4324\/9780203214015"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2005.00643.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1207\/S15328031US0104_02"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2005.01244.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/sim.2331"},{"key":"e_1_2_6_24_2","article-title":"Modelling the impact on Hepatitis C transmission of reducing syringe sharing: London case study","author":"Vickerman P","year":"2007","journal-title":"IJE"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/pubmed\/fdh109"},{"key":"e_1_2_6_26_2","volume-title":"Hepatitis C Action Plan for England","year":"2004"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2893.2006.00725.x"},{"key":"e_1_2_6_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/25.1.204"},{"issue":"1060","key":"e_1_2_6_29_2","first-page":"50","article-title":"Injecting behaviours and prevalence of hepatitis B, C and D markers in New Zealand injecting drug user populations","volume":"111","author":"Kemp R","year":"1998","journal-title":"N Z Med J"},{"key":"e_1_2_6_30_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365549509032726"},{"key":"e_1_2_6_31_2","doi-asserted-by":"publisher","DOI":"10.1258\/095646205774763180"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyh019"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042560-199802001-00004"},{"key":"e_1_2_6_34_2","doi-asserted-by":"publisher","DOI":"10.3109\/00365549609027145"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.35.12.3274-3277.1997"},{"key":"e_1_2_6_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.2001.961217878.x"},{"key":"e_1_2_6_37_2","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2000.tb139199.x"},{"key":"e_1_2_6_38_2","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.91.1.42"},{"key":"e_1_2_6_39_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0376-8716(98)00028-3"},{"key":"e_1_2_6_40_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0955-3959(02)00092-0"},{"key":"e_1_2_6_41_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.qai.0000219788.73539.47"}],"container-title":["Journal of Viral Hepatitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2893.2007.00855.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2893.2007.00855.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,11]],"date-time":"2023-10-11T16:31:30Z","timestamp":1697041890000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2893.2007.00855.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,30]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1111\/j.1365-2893.2007.00855.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2893.2007.00855.x","archive":["Portico"],"relation":{},"ISSN":["1352-0504","1365-2893"],"issn-type":[{"value":"1352-0504","type":"print"},{"value":"1365-2893","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,30]]}}}